| Literature DB >> 34188341 |
Xiaobin Dong1, Luyao Liu1, Yunping Tu1, Jing Zhang1, Guijun Miao1, Lulu Zhang1, Shengxiang Ge2, Ningshao Xia2, Duli Yu1,3, Xianbo Qiu1.
Abstract
PCR has been widely used in different fields including molecular biology, pathogen detection, medical diagnosis, food detection and etc. However, the difficulty of promoting PCR in on-site point-of-care testing reflects on challenges relative to its speed, convenience, complexity, and even cost. With the emerging state-of-art of microfluidics, rapid PCR can be achieved with more flexible ways in micro-reactors. PCR plays a critical role in the detection of SARS-CoV-2. Under this special background of COVID-19 pandemic, this review focuses on the latest rapid microfluidic PCR. Rapid PCR is concluded in two main features, including the reactor (type, size, material) and the implementation of thermal cycling. Especially, the compromise between speed and sensitivity with microfluidic PCR is explored based on the system ratio of (thermal cycling time)/(reactor size). Representative applications about the detection of pathogens and SARS-CoV-2 viruses based on rapid PCR or other isothermal amplification are discussed as well.Entities:
Keywords: COVID-19; Microfluidics; Pathogen Detection; Point-of-Care Testing (POCT); Rapid PCR; Thermal Cycling
Year: 2021 PMID: 34188341 PMCID: PMC8223007 DOI: 10.1016/j.trac.2021.116377
Source DB: PubMed Journal: Trends Analyt Chem ISSN: 0165-9936 Impact factor: 12.296
Fig. 1Procedure of the detection to SARS-CoV-2 with PCR.
Fig. 2A brief summarization of typical PCR reactors.
Fig. 3(A) Continuous-flow chip including PCR and electrophoresis [29]. (B) Instrument-free CPCR [36]. (C) Rotary PCR system [39]. (D) Non-contact photonic heating to the PCR reagent itself [47]. (E) Non-contact photonic heating to AuBPs mixed with PCR reagent [48]. (F) Microwave heating to PCR reagent [49].
Fig. 4Representative commercialized devices for rapid detection to SARS-CoV-2 viruses.
The system ratio γ and the corresponding limit of detection of different devices.
| Category | Characteristics | Thermal cycling time (min) | Reactor size (μL) | System ratio γ (min/μL) | Limit of detection | Reference |
|---|---|---|---|---|---|---|
| γ ≥ 5.88 | Low compatibility with clinical diagnosis of infectious diseases | ~ 2.16 | ~ 0.02 | 108 | 75 copies/single well | [ |
| 6 | 0.1 | 60 | NA | [ | ||
| 26.5 | 1.3 | 20.38 | 0.1 ng/μL | [ | ||
| 25.5 | 1 | 25.5 | 12 ag (~2 copy number) | [ | ||
| 50 | 8.5 | 5.88 | 80 ng/μL | [ | ||
| γ < 5.88 | High compatibility with clinical diagnosis of infectious diseases | 24 | 20 | 1.2 | 1 pg | [ |
| 10 | 10 | 1 | 1 ng/μL | [ | ||
| 30 | 40 | 0.75 | 1.0 | [ | ||
| 20 | 25 | 0.8 | 10 copies | [ | ||
| 7.5 | 10 | 0.75 | 1 pg/μL | [ | ||
| 30 | 40 | 0.75 | 1.0 | [ | ||
| 30 | 40 | 0.75 | 1.0 | [ | ||
| 6.14 | 25 | 0.09 | 125 cfu/μL | [ | ||
| 13.8 | 50 | 0.276 | 10−3 ng/μL | [ | ||
| 20 | 6 | 3.33 | NA | [ | ||
| 30 | 10 | 3 | 108 copies/μL | [ | ||
| 76 | 25 | 3.04 | NA | [ | ||
| 50 | 20 | 2.5 | NA | [ | ||
| Commercialization | 25 | 5–30 | 0.83–5 | 200 copies/μL | [ | |
| 30 | 25–50 | 0.75 | 1112 copies/mL | [ | ||
| ≤11 (positive) | 25–50 | 0.22–1.2 | 900 copies/mL | [ | ||
| ~ 30 (positive) | 25–50 | 0.6–1.8 | 0.0200 PFU/mL | [ | ||
| ≤5 (positive) | 25–50 | 0.1–0.52 | 125 genome equivalents/mL | [ | ||
| ~ 45 | 25–50 | 0.9–1.8 | Heat-inactivated virus ATCC VR-1986HK 500 copies/mL | [ |